Clindamycin palmitate hydrochloride dispersion tablet and its preparation method

A technology of clindamycin hydrochloride and palmitate, which is applied in the directions of medical preparations containing active ingredients, pharmaceutical formulations, organic active ingredients, etc. Effect

Active Publication Date: 2006-08-30
GUANGZHOU YIPINHONG PHARMA +4
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] In order to solve the shortcoming of the single oral dosage form of clindamycin hydrochloride palmitate in the prior art, improve the bioavailability of insoluble drugs, exert the maximum drug effect with the smallest dose, and reduce the toxic and side effects of drugs, the present invention develops clindamycin hydrochloride Purpose of Vegan Palmitate Dispersible Tablets

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] 1. Prescription: The prescription composition of clindamycin hydrochloride palmitate dispersible tablets is as follows: (37.5mg specification is calculated as 1000 tablets), which contains:

[0040] Clindamycin palmitate hydrochloride 37.5g (calculated as clindamycin)

[0041] Low-substituted hydroxypropyl cellulose 200g

[0042] Lactose 100g

[0043] Carboxymethyl Starch Sodium 30g

[0044] Croscarmellose Sodium 20g

[0045] Poloxamer 10g

[0046] Stevia 5g

[0047] Talc powder 15g

[0048] Magnesium Stearate 15g

[0049] Food flavor 20ml

[0050] Pure water 70ml

[0051] 2. Method 1: The preparation method of clindamycin palmitate hydrochloride dispersible tablets is as follows:

[0052](a) take by weighing the clindamycin hydrochloride palmitate and adjuvant of prescription quantity; (b) adjuvant materials such as low-substituted hyprolose, lactose, cross-linked carmellose sodium are placed in a mixer and mixed eve...

Embodiment 2

[0058] 1. Prescription: The prescription composition of clindamycin hydrochloride palmitate dispersible tablets is as follows: (1000 tablets for 75 mg), which contains:

[0059] Clindamycin palmitate hydrochloride 75g (calculated as clindamycin)

[0060] Low-substituted hydroxypropyl cellulose 150g

[0061] Lactose 80g

[0062] Carboxymethyl Starch Sodium 30g

[0063] Croscarmellose Sodium 10g

[0064] Poloxamer 15g

[0065] Stevia 5g

[0066] Talc powder 15g

[0067] Magnesium Stearate 15g

[0068] Fragrance 20ml

[0069] Pure water 60ml

[0070] 2. Preparation method: The preparation method of clindamycin palmitate hydrochloride dispersible tablet is the same as that in Example 1.

Embodiment 3

[0072] 1. Prescription: The prescription composition of clindamycin hydrochloride palmitate dispersible tablets is as follows: (150 mg is calculated as 1000 tablets), which contains:

[0073] Clindamycin palmitate hydrochloride 150g (calculated as clindamycin)

[0074] Low-substituted hydroxypropyl cellulose 100g

[0075] Lactose 60g

[0076] Carboxymethyl Starch Sodium 40g

[0077] Croscarmellose Sodium 15g

[0078] Poloxamer 15g

[0079] Stevia 6g

[0080] Talc powder 20g

[0081] Magnesium Stearate 15g

[0082] Fragrance 25ml

[0083] Pure water 60ml

[0084] 2. Preparation method: The preparation method of clindamycin palmitate hydrochloride dispersible tablet is the same as that in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A dispersing tablet of clindamycin hydrochloride palmitate contains proportionally clindamycin hydrochloride palmitate, diluent, disintegrant, solubilizer, flavouring and lubricant. Its preparing process is also disclosed, which features use of empty particles and dry granulating.

Description

technical field [0001] The invention relates to clindamycin hydrochloride palmitate dispersible tablets for treating various infectious diseases caused by gram-positive bacteria and anaerobic bacteria and a preparation method thereof. Background technique [0002] Clindamycin palmitate hydrochloride is a kind of antibacterial drug successfully developed by Upjohn Company, and its trade name mainly contains Cleocin Pediatric®, and the foreign oral dosage form is mainly dry syrup. This product was also successfully developed in China in the 1990s, and its oral dosage form is granules. [0003] Clindamycin palmitate hydrochloride is the prodrug of clindamycin, and its pharmacology and toxicology data show that after oral administration of clindamycin palmitate hydrochloride, it can be completely absorbed and can be quickly hydrolyzed into free Clindamycin works, and clindamycin has a higher antibacterial effect, which is 2-8 times that of lincomycin. Clindamycin is antibacter...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7056A61K9/20A61P31/04
Inventor 李振压兰志银李锋
Owner GUANGZHOU YIPINHONG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap